|
rs61764370
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers.
|
25940428 |
2016 |
|
rs61764370
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers.
|
25940428 |
2016 |
|
rs61764370
|
|
Malignant Neoplasms
|
|
0.050 |
GeneticVariation
|
BEFREE |
rs61764370 is not associated with risk of ovarian or breast cancer nor with clinical outcome for patients with these cancers.
|
25940428 |
2016 |
|
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
|
rs61764370
|
|
Malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome.
|
24890702 |
2014 |
|
rs61764370
|
|
Dry skin
|
|
0.010 |
GeneticVariation
|
BEFREE |
A significant association with dry skin and global cetuximab-related toxicity was observed for the KRAS-LCS6 (rs61764370) variant (p<0.05); carriers of the G allele (genotypes TG+GG) in the dominant model were observed to have a decreased susceptibility of developing dry skin (OR=0.287 [95%CI=0.119-0.695]).
|
27938998 |
2016 |
|
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC.
|
26162609 |
2015 |
|
rs61764370
|
|
Colorectal Carcinoma
|
|
0.030 |
GeneticVariation
|
BEFREE |
Eight miRSNPs (rs1804191, rs397768, rs41116 in APC; rs1137918, s227091, rs4585 in ATM; rs712, rs1137282, rs61764370 in KRAS; rs8674 in PARP1 and rs16950113 in SMAD7) were tested for their association with CRC risk in a case-control study (1111 cases and 1469 healthy controls).
|
29048575 |
2017 |
|
rs61764370
|
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene.
|
20647319 |
2010 |
|
rs61764370
|
|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene.
|
20647319 |
2010 |
|
rs61764370
|
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
In this study, we investigated a hypothesized association between an increased risk of OC and a variant allele of KRAS at rs61764370, referred to as the KRAS-variant, which disrupts a let-7 miRNA binding site in this oncogene.
|
20647319 |
2010 |
|
rs61764370
|
|
Breast Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.
|
22436609 |
2012 |
|
rs61764370
|
|
Malignant neoplasm of breast
|
|
0.020 |
GeneticVariation
|
BEFREE |
KRAS rs61764370 is associated with HER2-overexpressed and poorly-differentiated breast cancer in hormone replacement therapy users: a case control study.
|
22436609 |
2012 |
|
rs61764370
|
|
Endometriosis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Lack of an Association between a Polymorphism in the KRAS 3' Untranslated Region (rs61764370) and Endometriosis in a Large European Case-Control Study.
|
31185482 |
2019 |
|
rs61764370
|
|
Breast Cancer, Familial
|
|
0.010 |
GeneticVariation
|
BEFREE |
Our data do not support the hypothesis that the KRAS variant rs61764370 is implicated in the aetiology of sporadic or of familial breast cancer.
|
22436609 |
2012 |
|
rs61764370
|
|
Endometriosis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Our results do not support the suggestion that carrying the minor allele at rs61764370 contributes to a significant number of endometriosis cases and rs61764370 is, therefore, unlikely to be a useful marker of endometriosis risk.
|
23010532 |
2012 |
|
rs61764370
|
|
Secondary malignant neoplasm of colon and/or rectum
|
|
0.010 |
GeneticVariation
|
BEFREE |
Recent studies have reported associations between a variant allele in a let-7 microRNA complementary site (LCS6) within the 3'untranslated region (3'UTR) of KRAS (rs61764370) and clinical outcome in metastatic colorectal cancer (mCRC) patients receiving cetuximab.
|
23167843 |
2012 |
|
rs61764370
|
|
Non-Small Cell Lung Carcinoma
|
|
0.020 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
ovarian neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
Carcinoma, Ovarian Epithelial
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
Malignant neoplasm of ovary
|
|
0.030 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
Hereditary Breast and Ovarian Cancer Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
Recently, a variant allele in the 3'UTR of the KRAS gene (rs61764370 T>G) was shown to be associated with an increased risk for developing non-small cell lung cancer, as well as ovarian cancer, and was most enriched in ovarian cancer patients from hereditary breast and ovarian cancer families.
|
20676756 |
2011 |
|
rs61764370
|
|
Neoplasm Metastasis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Results demonstrated that TT genotype and T allele of rs712 were associated with the increased risk of CRC; the patients with GG genotype and G allele of rs61764370 had a shorter survival and a higher risk of relapse or metastasis of CRC.
|
26515332 |
2016 |
|
rs61764370
|
|
Sarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
The objective of the present study was to explore the molecular mechanism with which a single nucleotide polymorphism (rs61764370) interferes with the interaction between the 3'-untranslated region (3'-UTR) of Kirsten rat sarcoma viral oncogene homolog (KRAS) and let-7a, and its association with the metastasis of osteosarcoma (OS).
|
27430246 |
2016 |
|
rs61764370
|
|
Malignant neoplasm of soft tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
The objective of the present study was to explore the molecular mechanism with which a single nucleotide polymorphism (rs61764370) interferes with the interaction between the 3'-untranslated region (3'-UTR) of Kirsten rat sarcoma viral oncogene homolog (KRAS) and let-7a, and its association with the metastasis of osteosarcoma (OS).
|
27430246 |
2016 |